EVŌQ Bio said that it had positive feedback from the FDA following a pre-IND meeting about EVQ-218 inhaled non-ionic silver nanoparticle, which the company is developing for the treatment of pulmonary bacterial infections in cystic fibrosis patients with funding from the Cystic Fibrosis Foundation. According to parent company EVŌQ Nano’s web site, an IND submission and Phase 1 trial are planned for 2025.
The company says that EVQ-218 has demonstrated efficacy against 64 strains of drug-resistant bacteria and 14 biofilms, as well as various yeasts and fungi, without developing resistance. In addition, the company reports that the inhaled silver nanoparticles has not presented any safety or toxicity concerns in in vivo studies.
EVŌQ Nano CEO Shaun Rothwell commented, “The positive response from the FDA to our nanomedicine platform is a major milestone in the development of a new treatment for patients with cystic fibrosis and other bacterial lung infections.”
Read the Evoq Bio press release.
